InvestorsHub Logo
Followers 7
Posts 141
Boards Moderated 0
Alias Born 07/31/2015

Re: JTrader post# 104

Monday, 09/19/2016 6:35:18 PM

Monday, September 19, 2016 6:35:18 PM

Post# of 138
Now that we know their tech works -- at least for this first tested indication -- even with slightly less robust numbers in longer read outs, they still will go to market (easily and perhaps quickly) as THE new standard of care -- since current treatment is to send them home for total home care. Early 2a trail results see these patients becoming able to take care of themselves. It's night and day.

Sure it is early -- but we have so much more than we expected --- perhaps even at much later points in the current 2a trial. Based on the conference call, I would think they should see as good if not better results with the new cohort (partial spinal fractures, not total). And they can work long term toward giving everyone 20m cells - the newly approved number that they have yet to use. That seems to be the most impressive thing here - better, earlier results and not even using the max dosage yet. Hard not to get excited.

It is early in this trial. But this is a platform drug opportunity where it looks like their first go (trial paid for partially by partner) is going to be a winner. Great management as well so I was buying with them and hoping, and frankly it didn't take long, but some summer days kinda sucked!

Everybody is smiling big today. if you doubt, just look at the recent volume. The move from $3 to $4 came after the video of one of the patients came out where he is now lifting weights -- in 90 days. Talking, eating, writing. This guy signed his trial consent form by holding the pen in his mouth and others moved the paper.

Today's move up and strong close was because of the data. More to come.